文献速递浆细胞疾病

多发性骨髓瘤初始治疗中获得完全缓解对后续结局的影响及其预测因素

Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome.
PubMed 文献 · Am J Hematol · 2022-01-03

在常规临床环境中评估1869例新诊断多发性骨髓瘤患者,以诊断后24个月内血清和尿免疫固定电泳至少2次阴性定义完全缓解(CR)。24个月地标分析显示,CR组 vs 非CR组中位无进展生存期29.8 vs 20.9个月(p≤.0002),中位总生存期104 vs 70个月(p<.0001)。CR的获益在调整FISH、ISS、性别、移植状态和受累重链后仍存在。

要点

  • 诊断后2年内获得CR与PFS和OS改善相关。
  • CR组中基线FISH和ISS分期与PFS或OS无关。
  • CR队列中年龄>75岁、男性、低白蛋白血症和非IgG受累重链预测OS较差。

核心结论

  • 诊断后2年内获得CR与生存结局改善相关,并中和FISH和ISS风险的影响,在临床实践队列中证实了临床试验环境的观察。

研究设计与样本

  • 在常规临床环境中评估1869例新诊断多发性骨髓瘤患者,这些患者在诊断后24个月内至少有2次血清和尿单克隆蛋白免疫固定电泳研究可用。
  • 将血清和尿免疫固定电泳至少2次阴性者归类为获得CR,并以24个月为地标进行分析。

主要发现

  • CR组 vs 非CR组中位无进展生存期29.8 vs 20.9个月(p≤.0002)。
  • CR组 vs 非CR组中位总生存期104 vs 70个月(p<.0001)。
  • 获得CR的影响在调整FISH、ISS、性别、移植状态和受累重链后仍保留。
  • 在获得CR的患者中,基线FISH和ISS分期与PFS或OS无关。
  • 在CR队列中,年龄>75岁、男性、低白蛋白血症和非免疫球蛋白G受累重链被确定为总生存期较差的预测因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Achievement of a complete response (CR) in multiple myeloma (MM) correlates with improvement in survival outcomes; however, its impact on prognostic variables at baseline outside of clinical trial settings is not well described. We sought to determine the impact of achieving a CR within 2 years from diagnosis, its effect on the prognostic value of fluorescence in situ hybridization (FISH) and International Staging System (ISS) risk, and examined additional predictors of outcome among those achieving a CR in a routine clinical setting. We evaluated 1869 newly diagnosed MM patients who had ≥ 2 monoclonal protein immunofixation studies in the serum and urine available within 24 months from diagnosis, categorizing those with ≥ 2 negative serum and urine immunofixations as achieving CR. With a landmark at 24 months, median progression-free survival (PFS) for CR versus non-CR patients was 29.8 versus 20.9 months (p ≤ .0002); median overall survival (OS) was 104 versus 70 months (p < .0001). The impact of achieving a CR was retained after adjusting for FISH, ISS, sex, transplant status, and involved heavy chain. Baseline FISH and ISS stage were not associated with PFS or OS among patients achieving a CR. The following variables were found as predictors of inferior OS within the CR cohort: age > 75 years, male gender, hypoalbuminemia, and non-immunoglobulin G involved heavy chain. Our study confirms that achievement of CR within 2 years from diagnosis is associated with improvement in survival outcomes and neutralization of the impact of FISH and ISS risk, thereby confirming observations from the clinical trial setting among a clinical practice cohort.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Kaddoura M, Binder M, Dingli D, et al. Impact of achieving a complete response to initial therapy of multiple myeloma and predictors of subsequent outcome. Am J Hematol. 2022. PMID: 34978743. doi:10.1002/ajh.26439

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。